ERBB2 and neoplasm: In the Calu-3 model, treatment with HER2-TTC at all doses (125, 250, or 500 kBq/kg) resulted in almost complete tumor eradication with T/Cs of 0.10, 0.08, and 0.08, respectively (Figure 3C,D).